Additional research has revealed that GFAP levels rise before other biomarkers (i.e., p-tau and NfL), suggesting that GFAP may be an early indicator of AD pathology, even before tangle formation and widespread neurodegeneration occur [101]. This evidence concerns the gene MAPT and Alzheimer disease.